Poly(ADP-ribose) Polymerase Inhibitor Combinations in First-Line Metastatic Castration-Resistant Prostate Cancer: Increasing Toxicity With Unclear Benefits.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 37847874.
- Also identified by DOI 10.1200/JCO.23.01502 and PMC identifier 10861006.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Positive phase III trials are not truly practice changing if they do not accurately inform on the best options for patients
Medical subject headings
- Prostatic Neoplasms, Castration-Resistant
- Antineoplastic Agents